---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-25-000056"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:16.214792+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement

## Summary
- First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.
- Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.
- Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.
- Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.
- Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones.

## SEC filing metadata
- accession: 0001680367-25-000056
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/0001680367-25-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/sttk-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-25-000056
- JSON: https://secwatch.observer/filing/0001680367-25-000056.json
- Plain text: https://secwatch.observer/filing/0001680367-25-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.